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Abstract 
A novel infectious disease, caused by 2019 Novel Coronavirus (2019‑nCoV) is responsible for the recent outbreak of 
severe respiratory disease. The 2019‑nCoV spread rapidly and reaching epidemic proportions in many countries of 
the world. ACE2 was identified as a key receptor for 2019‑nCoV infections. Excessive form of soluble ACE2 rescues 
cellular ACE2 activity which has a protective role in acute lung failure and neutralizes the virus. The short half‑life of 
ACE2 is a major limitation to its practical application. Nanoparticle‑based drug delivery systems are one of the most 
widely investigated approaches for developing novel therapies for a variety of diseases. Nevertheless, nanoparticles 
suffer from the rapid removal from the bloodstream by the reticuloendothelial system (RES). A noncovalent attach‑
ment of nanoparticles to RBCs increases their half‑life in blood and allows transient accumulation in the lungs, while 
decreases their uptake by the liver and spleen. Connecting the recombinant ACE2 into the surface of nanoparticles 
that were attached to RBCs can be a potential therapeutic approach for 2019‑nCoV infection through increasing their 
lung targeting to naturalize the virus and also acting as a bioreactor in the blood circulation to decrease serum level 
of Angiotensin II and protects lungs from injury/ARDS.
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Introduction
The 2019 Novel Coronavirus (2019-nCoV) or SARS-
CoV-2 is an enveloped RNA virus that it is spreading 
rapidly and scientists are trying to discover drugs for an 
effective treatment [1]. This coronavirus induces exces-
sive and abnormal non-effective host immune responses 
that are associated with acute respiratory distress syn-
drome (ARDS) and severe lung pathology, leading to 
death [2]. Spike (S) proteins of coronaviruses, includ-
ing SARS-CoV and the 2019-nCoV, correlate with cel-
lular receptors to mediate infection of their target cells 
[3]. It has been reported that the angiotensin-converting 
enzyme II (ACE2) plays an important role in the entry of 
the virus into cells, thus the ACE2-expressing cells may 
act as target cells and are susceptible to 2019-nCoV infec-
tion [4]. ACE2 is mainly expressed in alveolar epithelial 
type II cells. In most 2019-nCoV infected patients, lungs 
are heavily infected by the virus and alveolar epithelial 
cells serve as a viral reservoir [5]. ACE2 is also expressed 
in multiple extrapulmonary tissues including the human 
heart, kidneys, blood vessels, and intestine that might 
reveal the multiorgan dysfunction observed in patients 
[6, 7]. Researchers showed that 2019-nCoV directly 
infects and multiplies within the human blood ves-
sel and kidney organoids [8]. Overexpression of human 
ACE2 enhanced disease severity in a mouse model of 
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SARS-CoV infection, demonstrating that ACE2-depend-
ent viral entry into cells is a critical step [9].
Renin–angiotensin system in human coronavirus 
pathogenesis
There are two forms of ACE2. The full-length ACE2 is a 
type I integral membrane protein and the soluble form 
of ACE2 lacks the anchoring site and circulates in small 
amounts in the blood [10]; it has been shown to block the 
binding of the SARS-CoV spike protein to its receptor. 
ACE2 is a carboxypeptidase and is an ACE homologous. 
These receptors play critical functions in the renin-angi-
otensin system (RAS). ACE cleaves angiotensin I (Ang I) 
to form angiotensin II (Ang II); Ang II, the main active 
RAAS component, exerts its effects mainly via angio-
tensin II type 1 receptors (AT1R). Major effects of Ang 
II include vasoconstriction, renal sodium reabsorption 
and potassium excretion, aldosterone synthesis, blood 
pressure elevation, and induction of inflammatory and 
pro‐fibrotic pathways [11, 12], while, ACE2 negatively 
regulates the RAS and cleaves Ang II to formation of 
angiotensin 1–7 (Ang 1–7) which opposes the actions 
of Ang II [3, 12, 13]. Ang 1–7 exerts vasodilating, anti‐
inflammatory, and anti‐fibrotic effects through binding to 
the Mas receptor [14]. Imai et  al. showed that the RAS 
has a crucial role in severe acute lung injury and exces-
sive ACE2 rescues cellular ACE2 activity which has a 
protective role in acute lung failure [13]. Indeed, Kuba 
et al. demonstrated that SARS CoV and the Spike protein 
of the SARS-CoV reduce ACE2 expression (but not ACE) 
in mice, contributing to severe lung failure [15].
Recombinant ACE2 as a decoy receptor 
for 2019‑nCoV
In vitro studies in monkey kidney cells, Vero E6, showed 
that a soluble form of ACE2 blocked association of the 
S1 domain with Vero E6 cells thus SARS-CoV replication 
was blocked [16]. Moreover, ACE2 fused to the Fc por-
tion of immunoglobulin has just been described for high-
affinity binding to the receptor-binding domain (RBD) 
of SARS-CoV and 2019-nCoV and potently neutralized 
SARS-CoV and 2019-nCoV in  vitro [3]. Therefore, the 
rACE2 protein may be a potential therapeutic approach 
in the management of emerging lung disorders that suffer 
from ARDS [15, 17]. Nevertheless, the short half-life of 
rACE2 is the main limitation to its practical application 
[3].
Nanoparticle‑based targeted drug delivery
Successfully, in recent decades, nanoparticle-based drug 
delivery systems have been employed as experimentally 
and clinically to improve the efficacy of many drugs and 
therapeutic molecules. The field of nanomedicine pro-
vides distinct advantages over free drugs including target-
ing any organs while avoiding off-targets, and sustained 
release for improving the current treatment strategies for 
cancer and other diseases. But nanoparticles (NPs) suf-
fer from the rapid clearance from the bloodstream by the 
reticuloendothelial system (RES) principally located in 
the liver and spleen, thereby limiting the dose available 
for the disease site. Due to this reason and other unfa-
vorable factors, nanocarriers are not able to accumulate 
in many sites of therapeutic interest [18–20]. Erythro-
cytes are the particularly attractive vascular carrier for 
drug delivery of wide varieties of therapeutic agents to 
promote their biodistribution, pharmacokinetics, phar-
macodynamics, and controlled release. RBC hitchhik-
ing is a universal solution for dominant liver uptake and 
limited target organ deposition of nanocarriers as a drug 
delivery system. No damaging coupling to RBCs may 
prolong the lifetime of NPs in the circulation [21].
Hypothesis and evaluation
Recently, it has been reported that the serum level of 
Ang II is significantly raised in 2019-nCoV infected 
patients and shows a linear positive correlation to viral 
load and lung injury [22]. Activation of the RAS causes 
extensive endothelial dysfunction and differing degrees 
of multiple organ (heart, kidney, and lung) injuries [23]. 
ACE2 has two different functions, both as the entry 
receptor of SARS-CoV causes to worsen the disease, 
and also as a negative regulator of the RAS, protect the 
lung from injury. Findings suggest that the soluble form 
of ACE2 decreases viral spread through competitively 
binding with 2019-nCoV and neutralizes the virus simi-
lar to a decoy receptor. In this way, it protects the lung 
from injury through saving cellular ACE2 activity and 
negatively regulates the RAS. Non-covalent attach-
ments of NPs to the surface of RBCs (RBCs-NPs com-
plex) increases their level in the blood without detectable 
changes in RBC circulation. This complex improves the 
blood pharmacokinetics and provides transient accu-
mulation in the lungs while concurrently avoids their 
uptake by liver and spleen [18, 19, 24]. After several 
hours, NPs detach from the surface of RBCs, presum-
ably due to shear force and interactions with vascular 
cells and ultimately are taken up by the liver and the 
spleen [24]. Recently, it has been reported that when 
RBCs are squeezed through the lung narrow capillaries, 
the NPs detach from the RBCs and transfer to the pulmo-
nary capillary endothelial cells. Therefore, NPs, but not 
RBCs, accumulate transiently in the pulmonary vascula-
ture [18, 19]. It can be a potential therapeutic approach 
for coronavirus infection. To use ACE2 as a treatment to 
Page 3 of 5Aghili et al. J of Biol Res-Thessaloniki           (2020) 27:17  
2019-nCoV-infected patients, we propose to fuse soluble 
form of recombinant ACE2 (rACE2) into the exposed 
surface of NPs that were attached to RBCs (therapeutic 
triple complex) and thereby we expect to achieve several 
results including:
• Increase the transient accumulation of rACE2 in 
highly vascularized organs like lungs, heart and kid-
neys.
• Extending the lifespan of the circulating rACE2.
• The therapeutic triple complex acts as a bioreactor 
in the blood circulation and decreases serum level of 
Ang II with cleavage it and inhibits severe acute lung 
injury/ARDS.
For this purpose, at first NPs adsorb onto the RBCs 
ex vivo. Spherical (PSNP) NPs can readily adhere to RBCs 
membrane by incubation at particle/RBC ratios up to 
100:1. Particle adhesion to RBCs membrane is likely due 
to electrostatic and hydrophobic interactions between 
PSNP and the RBC. After adsorption of NPs to RBCs, 
rACE2 passively will be adsorbed onto the exposed car-
boxylated surface of NPs. After injection via an intravas-
cular catheter, the therapeutic triple complex augments 
the accumulation of rACE2 in highly vascularized organs, 
first of all, lungs. NPs attached to the rACE2, through the 
lung narrow capillaries, transfer from the RBCs to the 
pulmonary capillary endothelium under the shear force 
and interactions with vascular cells [18, 19] (Fig. 1).
Effect of nanoparticles on biocompatibility 
of carrier RBCs
RBCs are naturally able to transport various cargoes 
throughout the circulatory system. RBC drug delivery 
systems represent viable (and, in some cases, preferable) 
alternatives to synthetic carriers; however, impairment of 
biocompatibility of the carrier RBCs and other adverse 
and unintended effects may cause other problems. Dos-
ing, timing, and regimens of administration of carrier 
RBCs or targeted agents need to be assessed separately 
and adjusted for these new parameters of their behavior 
and influences in the body [25]. Attachment of NPs to 
the surface of carrier RBCs can lead to changes in circu-
lation time, immunogenicity, biodistribution elimination 
pathways, and pharmacodynamics [26]. These changes 
in the pharmacokinetics of NPs imposed by carrier 
RBCs are beneficial for many drug delivery targets. To 
be clinically useful, NPs must not begin severe adverse 
effects on RBCs at loadings necessary for therapeu-
tic applications [27]. In several studies, using two types 
of distinct NPs [PSNP and Lysozyme-dextran nano-
gels (LDNGs)], potential adverse and sensitizing effects 
of surface adsorption of NPs on the mouse and human 
RBCs were assessed. The seminal studies reported that 
RBCs may serve as “super-carriers” for NPs, as non-
covalent attachment of PSNP to murine RBCs markedly 
alters the biodistribution of the NP in a manner advanta-
geous to treatment of many diseases. PSNPs were used as 
a representative NP to evaluate RBCs as cellular carriers 
for NP delivery [27, 28]. According to these reports, the 
attachment of PSNP particle does not alter RBCs mor-
phology [18, 19, 21, 24]. However, different studies have 
reported that the adsorption of PSNP beads onto RBCs 
causes their agglutination and sensitizes RBCs to damage 
by osmotic, mechanical and oxidative stress [27], whereas 
the adsorption of NPs made from soft biodegradable 
materials, LDNGs, does not induce negative effects on 
RBCs. Probable key physicochemical differences between 
LDNGs and PSNPs are likely responsible for the observed 
differences in their RBC sensitization and compatibility. 
LDNGs are less rigid, biodegradable and biocompatible 
compared to PSNPs. LDNGs do not induce NP-mediated 
damage to RBCs at loadings which PSNPs induce adverse 
effects [27, 28]. Therefore, the selection of the appropri-
ate NPs types based on the targets of the experiments is 
an important factor and should be carefully studied.
Conclusion
Recombinant ACE2 protein could not only be a treat-
ment to block the spreading of 2019-nCoV, but modula-
tion of the RAS could also be used to protect individuals 
with SARS. Fusing rACE2 into the exposed surface of 
NPs that were attached to RBCs, cause to extending the 
lifespan of the circulating rACE2 and increasing lung 
highly vascularized organs targeting and also act as a bio-
reactor in the blood circulation to decrease serum level 
of Ang II. Possibly this approach could also be used to 
protect individuals infected with other viruses such as 
SARS-CoV and avian influenza A strains, from develop-
ing acute severe lung failure and acute respiratory dis-
tress syndrome.
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Fig. 1 a Schematic of the therapeutic triple complex in blood circulation. b RBC–NPs complexes detach from RBCs in small capillaries, this process 
increases the rACE2 in lung capillaries and saving cellular rACE2 activity. c Also, it acts as a decoy for 2019‑nCoV and decrease viral spreading. The 
therapeutic triple complex acts as a bioreactor in the blood circulation and decreases serum level of Ang II with cleavage it to Ang 1–7
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